MedTrace Logo

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

NCT04782193 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-04-18

No results posted yet for this study

Summary

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B Cell Lymphoma

Conditions

  • B Cell Lymphoma

Interventions

BIOLOGICAL

CD19 and CD22 targeted prime CAR- T cells

A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously

Sponsors & Collaborators

  • Chongqing Precision Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Sanbin Wang, MD · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

  • Cheng Qian, PhD · Chongqing University Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-23
Primary Completion
2023-12-31
Completion
2024-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04782193 on ClinicalTrials.gov